| 2005 |
Between 2005 and 2011, the pharmacological efficacy tests of SMTP confirmed thrombolytic promotion, anti-inflammatory, and cerebral infarction improvement effects. |
| 2005 |
Confirmed thrombolytic promotion, anti-inflammatory, and cerebral infarction improvement effects in SMTP pharmacological efficacy tests (2005-2011). |
| 2005-02 |
Founded in February 2005 with the purpose of commercializing the medicinal seed discovered by Professor Keiji Renmi of the Fermentation Laboratory at Tokyo University of Agriculture and Technology. |
| 2005-02 |
Company establishment |
| 2007 |
Invested in our company in 2007. |
| 2011-11 |
In November 2011, non-clinical trials of TMS-007 were initiated. |
| 2011-11 |
Started non-clinical trials of TMS-007. |
| 2014-10 |
In October 2014, Phase I clinical trials of TMS-007 were started. |
| 2014-10 |
Started Phase I clinical trial of TMS-007. |
| 2015-10 |
In October 2015, Phase I clinical trials of TMS-007 were completed. |
| 2015-10 |
Completed Phase I clinical trial of TMS-007. |
| 2018-02 |
In February 2018, Phase II clinical trials of TMS-007 were started. |
| 2018-02 |
Started Phase II clinical trial of TMS-007. |
| 2018-06 |
In June 2018, an option agreement was signed to transfer the lead compound TMS-007 to BioGen for a total of $357 million. |
| 2018-06 |
Entered into an option agreement to license TMS-007 to Biogen. |
| 2021 |
© 2021 TMS Co., Ltd. |
| 2021-05 |
In May 2021, BioGen exercised its option rights for TMS-007. |
| 2021-05 |
Biogen exercised its option rights for TMS-007. |
| 2021-08 |
In August 2021, the first Phase II trial of TMS-007 was completed. |
| 2021-08 |
Completed the interim Phase II trial of TMS-007. |
| 2022-11 |
In November 2022, the company was listed on the Tokyo Stock Exchange Growth Market (ticker: 4891). |
| 2022-11 |
Listed on the Tokyo Stock Exchange Growth Market (ticker: 4891). |
| 2024-01 |
In January 2024, BioGen transferred the rights to TMS-007 to JIXING. |
| 2024-01 |
In January 2024, a strategic partnership agreement with JIXING was signed, securing development and sales rights for TMS-007 and JX09 in Japan. |
| 2024-01 |
Biogen transferred rights to TMS-007 to JIXING. |
| 2024-01 |
Entered into a strategic partnership agreement with JIXING and obtained development and sales rights for TMS-007 and JX09 in Japan. |
